Moderna Prices Upsized $2.6B Convertible Notes Offering
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna priced an upsized $2.6 billion offering of convertible senior notes. The company also purchased a hedge overlay intended to offset dilution up to a cap initially equal to a 175% premium to the stock price at pricing. This is a significant capital raise for a company with a market cap around $57 billion, and the upsizing suggests strong demand. The hedge overlay is designed to reduce potential dilution from conversion, which may be viewed positively by existing shareholders. The offering follows a period of high volatility and positive pipeline news, including the recent FDA approval of its flu vaccine and promising cancer vaccine data. Investors will watch for the final terms and use of proceeds, which were not detailed in the headline.
At the time of this announcement, MRNA was trading at $141.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $57B. The 52-week trading range was $22.28 to $176.66. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.